The landscape of gastrointestinal cancer treatment in 2025 has been shaped by several pivotal clinical developments, with advances in targeted therapies, immunotherapy strategies and optimized chemotherapy regimens offering new options for patients with pancreatic, colorectal and other GI malignancies.
Daraxonrasib receives FDA breakthrough designation for pancreatic cancer
In July, daraxonrasib (RMC-6236), an oral direct RAS(ON) multiselective inhibitor, received FDA breakthrough therapy designation for previously treated metastatic pancreatic ductal adenocarcinoma (PDAC) with KRAS G12X mutations. The decision was based on phase 1 RMC-6236-001 results showing a median progression-free survival of 8.8 months at the 300 mg daily dose in this population. A global phase 3 trial, RASolute-302, is underway to compare daraxonrasib with standard chemotherapy, with results expected in 2026.
Aspirin halves 3-year recurrence risk in PIK3CA-mutated colorectal cancer
Results from the phase 3 ALASCCA trial, presented at the ASCO Gastrointestinal Cancers Symposium, showed that aspirin taken for three years substantially reduced recurrence risk in nonmetastatic colorectal cancer patients with PI3K pathway alterations. Compared with placebo, aspirin lowered recurrence by 51% in patients with PIK3CA exon 9/20 mutations and by 58% for other PI3K pathway alterations. The findings expand a predictive biomarker-driven indication to about 40% of CRC patients and underscore the value of genomic testing and drug repurposing.
Leronlimab cleared for phase 2 trial in microsatellite-stable CRC
The FDA has cleared a phase 2, open-label, randomized study of leronlimab, a monoclonal antibody targeting CCR5, in relapsed or refractory microsatellite-stable colorectal cancer. The trial will assess leronlimab combined with trifluridine/tipiracil (TAS-102) and bevacizumab in roughly 60 CCR5-positive patients. The primary end point is overall response rate; secondary end points include overall survival and safety. The estimated primary completion date is June 2028.
PAXG outperforms mFOLFIRINOX as neoadjuvant therapy in PDAC
Final results from the phase 3 CASSANDRA trial, presented at the 2025 ASCO Meeting, found that the neoadjuvant PAXG regimen (cisplatin, nab‑paclitaxel, gemcitabine and capecitabine) was superior to modified FOLFIRINOX for resectable and borderline resectable PDAC. PAXG improved median event-free survival to 16.0 months versus 10.2 months with mFOLFIRINOX, and the 3-year EFS rate was 31% versus 13%. PAXG also produced higher disease control rates and more favorable pathological outcomes.
Intracellular checkpoint inhibition shows first clinical promise in metastatic CRC
First-in-human phase 1 data demonstrate the feasibility of targeting the intracellular immune checkpoint CISH in heavily pretreated metastatic colorectal cancer. Investigators administered autologous tumor-infiltrating lymphocytes with CRISPR/Cas9-mediated CISH knockout to enhance T-cell antitumor activity. The approach exhibited a favorable safety profile and produced a durable complete response in one patient, offering early clinical validation for intracellular checkpoint targeting as a complement to existing PD‑1/PD‑L1 strategies.
Leave a Reply